Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study
Thirty patients with pathologically confirmed advanced ICC received intravenous gemcitabine (1 g/m2) on Days 1 and 8 and oxaliplatin (85 mg/m2) Q3W for six cycles along with intravenous toripalimab (240 mg) Q3W and oral lenvatinib (8 mg) once daily for one year....Patients (21/30) with DNA damage response (DDR)-related gene mutations showed a higher ORR…
56P - Anti-PD1 antibody toripalimab, lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: A phase II clinical trial
The combination of toripalimab, lenvatinib with Gemox chemotherapy was tolerable and showed promising ORR in patients with advanced ICC. ORR was significantly associated with PD-L1 expression and DNA damage repair (DDR)-related mutations in tumor samples.